Completed
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
NCT04671303
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, +5 more
- Locations
-
- cancer hospital Chinese academy of medical sciences Beijing, Beijing Municipality, China